{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:14:38Z","timestamp":1761920078695,"version":"3.41.2"},"reference-count":26,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5,1]]},"abstract":"<jats:p>Background: Delayed-release dimethyl fumarate (DMF; also known as gastroresistant DMF) is indicated for relapsing multiple sclerosis (MS). The objective of this study was to explore the safety and tolerability of DMF when administered with interferon beta (IFN\u03b2) or glatiramer acetate (GA).<\/jats:p>\n               <jats:p>Methods: Patients with relapsing-remitting MS receiving established therapy with the same dose of IFN\u03b2 or GA for at least 12 months continued their prescribed therapy for 2 months (monotherapy period) and then received DMF 240 mg three times daily in addition to their prescribed MS therapy for 6 months (add-on therapy period). Safety and magnetic resonance imaging outcomes were monitored monthly.<\/jats:p>\n               <jats:p>Results: During the add-on therapy period, in the DMF+IFN\u03b2 (n = 57) and DMF+GA (n = 47) groups, the overall incidence of adverse events was 95% and 100%, respectively; the most common adverse events were flushing, diarrhea, and abdominal pain. In both groups, mean lymphocyte counts decreased but remained within normal limits, and hepatic transaminase levels increased transiently; no case met Hy's law criteria. There was no overall increased risk of infection. In both groups, gadolinium-enhancing lesion activity and new\/enlarging T2 lesions decreased compared with the monotherapy period (exploratory endpoints).<\/jats:p>\n               <jats:p>Conclusions: The safety profile of DMF taken with IFN\u03b2 or GA was acceptable and consistent with the known safety profile of DMF monotherapy.<\/jats:p>","DOI":"10.7224\/1537-2073.2015-020","type":"journal-article","created":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T16:39:46Z","timestamp":1446223186000},"page":"138-146","source":"Crossref","is-referenced-by-count":6,"title":["Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis"],"prefix":"10.7224","volume":"18","author":[{"given":"Jonathan","family":"Calkwood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Vollmer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Fox","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Novas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah I.","family":"Sheikh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vissia","family":"Viglietta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4242","reference":[{"key":"2020060301095485900_i1537-2073-18-3-138-b1","doi-asserted-by":"crossref","first-page":"e16664","DOI":"10.1371\/journal.pone.0016664","article-title":"Switching multiple sclerosis patients with breakthrough disease to second-line therapy","volume":"6","author":"Castillo-Trivino","year":"2011","journal-title":"PLoS One."},{"key":"2020060301095485900_i1537-2073-18-3-138-b2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1352458508096687","article-title":"Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis","volume":"15","author":"Gajofatto","year":"2009","journal-title":"Mult Scler."},{"key":"2020060301095485900_i1537-2073-18-3-138-b3","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1212\/WNL.0000000000000283","article-title":"Fingolimod after natalizumab and the risk of short-term relapse","volume":"82","author":"Jokubaitis","year":"2014","journal-title":"Neurology."},{"key":"2020060301095485900_i1537-2073-18-3-138-b4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1468-1331.2011.03648.x","article-title":"Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response","volume":"19","author":"Rio","year":"2012","journal-title":"Eur J Neurol."},{"key":"2020060301095485900_i1537-2073-18-3-138-b5","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1212\/WNL.0b013e318258f7d4","article-title":"Teriflunomide added to interferon-beta in relapsing multiple sclerosis: a randomized phase II trial","volume":"78","author":"Freedman","year":"2012","journal-title":"Neurology."},{"key":"2020060301095485900_i1537-2073-18-3-138-b6","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1212\/01.wnl.0000343880.13764.69","article-title":"GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study","volume":"72","author":"Goodman","year":"2009","journal-title":"Neurology."},{"key":"2020060301095485900_i1537-2073-18-3-138-b7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ana.23863","article-title":"Randomized study combining interferon and glatiramer acetate in multiple sclerosis","volume":"73","author":"Lublin","year":"2013","journal-title":"Ann Neurol."},{"key":"2020060301095485900_i1537-2073-18-3-138-b8","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med."},{"key":"2020060301095485900_i1537-2073-18-3-138-b9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1191\/1352458504ms1084oa","article-title":"An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis","volume":"10","author":"Vollmer","year":"2004","journal-title":"Mult Scler."},{"key":"2020060301095485900_i1537-2073-18-3-138-b10","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s10072-014-1800-y","article-title":"Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia","volume":"35","author":"La Mantia","year":"2014","journal-title":"Neurol Sci."},{"key":"2020060301095485900_i1537-2073-18-3-138-b11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jns.2011.01.016","article-title":"Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity","volume":"303","author":"Siger","year":"2011","journal-title":"J Neurol Sci."},{"key":"2020060301095485900_i1537-2073-18-3-138-b12","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J Neurol."},{"key":"2020060301095485900_i1537-2073-18-3-138-b13","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med."},{"key":"2020060301095485900_i1537-2073-18-3-138-b14","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med."},{"key":"2020060301095485900_i1537-2073-18-3-138-b15","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria.\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"key":"2020060301095485900_i1537-2073-18-3-138-b16","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology."},{"key":"2020060301095485900_i1537-2073-18-3-138-b17","first-page":"45","article-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice","volume":"47","year":"2001","journal-title":"J Postgrad Med."},{"key":"2020060301095485900_i1537-2073-18-3-138-b18","unstructured":"World Medical Association. Declaration of Helsinki. Helsinki, Finland: World Medical Association; 1964."},{"key":"2020060301095485900_i1537-2073-18-3-138-b19","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE): Version 4.0. Rockville, MD: National Cancer Institute; May 28, 2009."},{"key":"2020060301095485900_i1537-2073-18-3-138-b20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.mayocp.2013.11.002","article-title":"Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies","volume":"89","author":"Wingerchuk","year":"2014","journal-title":"Mayo Clin Proc."},{"key":"2020060301095485900_i1537-2073-18-3-138-b21","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(08)61619-0","article-title":"Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study","volume":"372","author":"Kappos","year":"2008","journal-title":"Lancet."},{"author":"Bar-Or","key":"2020060301095485900_i1537-2073-18-3-138-b22","article-title":"Clinical efficacy and safety of oral BG-12 (dimethyl fumarate) in relapsing-remitting multiple sclerosis (RRMS): an integrated analysis of the phase 3 DEFINE and CONFIRM studies"},{"key":"2020060301095485900_i1537-2073-18-3-138-b23","doi-asserted-by":"crossref","first-page":"236","DOI":"10.7224\/1537-2073.2014-069","article-title":"Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate","volume":"17","author":"Phillips","year":"2015","journal-title":"Int J MS Care."},{"author":"Fox","key":"2020060301095485900_i1537-2073-18-3-138-b24","article-title":"Lymphocyte count reductions with delayed-release dimethyl fumarate: integrated analysis of the phase 2, phase 3, and extension studies"},{"year":"2013","key":"2020060301095485900_i1537-2073-18-3-138-b25","article-title":"Tecfidera [package insert]"},{"key":"2020060301095485900_i1537-2073-18-3-138-b26","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ene.12624","article-title":"Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in MS","volume":"22","author":"Kappos","year":"2015","journal-title":"Eur J Neurol."}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/18\/3\/138\/2092371\/1537-2073_2015-020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/18\/3\/138\/2092371\/1537-2073_2015-020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:11:50Z","timestamp":1752786710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/safety-and-tolerability-of-delayed-release-dimethyl-fumarate-administered-with-interferon-beta-or-glatiramer-acetate-in-relapsing-remitting-multiple-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2015-020","relation":{},"ISSN":["1537-2073"],"issn-type":[{"type":"print","value":"1537-2073"}],"subject":[],"published":{"date-parts":[[2016,5,1]]}}}